
|Videos|July 15, 2019
TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors
General Cancer
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: FDA Decisions and Clinical Advancements
2
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
3
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
4
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
5







































